Vanguard Investments Australia
LAB icon

Vanguard Investments Australia’s Standard BioTools LAB Stock Holding History

Vanguard Investments Australia’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-52,954
Closed -$48.7K – 2406
2026
Q1 		$48.7K Buy
+52,954
New +$64.1K ﹤0.01% 2365

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Investments Australia's LAB Position: Q2 2026 in Review

Vanguard Investments Australia sold out of Standard BioTools (LAB) in Q2 2026, closing a stake of 52,954 shares — an estimated $48.7K sold.

Vanguard Investments Australia first reported a position in LAB in Q1 2026 and held it in 1 quarter. The position peaked at $48.7K in Q1 2026. 128 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Vanguard Investments Australia reported no remaining Standard BioTools position as of Q2 2026 after selling out during the quarter.
  • Vanguard Investments Australia sold 52,954 Standard BioTools shares in Q2 2026, an estimated $48.7K.
  • Vanguard Investments Australia first reported a position in Standard BioTools in Q1 2026 and held it in 1 quarter.
  • Vanguard Investments Australia's Standard BioTools position peaked at $48.7K in Q1 2026.
  • 128 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.